Market Size of Cell Analysis Instruments Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 7.10 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Cell Analysis Instruments Market Analysis
The cell analysis instruments market is expected to register a CAGR of 7.1% over the forecast period.
COVID-19 had a significant impact on the cell analysis instruments market since cell count and viability tests were widely carried out during the pandemic. According to an article published in February 2022 in News Medical life sciences, the number of WBC cell counts is a crucial indicator of inflammation; higher than 11,000 WBCs per unit microliter of blood counts may affect COVID-19 patients' hospital discharge and mortality rates. Similarly, as per an article published in June 2021 in the BMC journal, a higher WBC count ( 6.16 10^9/L) should be given more attention in the treatment of COVID-19. Developments such as these put cell analysis at the forefront during the pandemic and have contributed greatly to the growth of the market, which is expected to continue its positive, upward trend in the coming years.
Another factor that has played into the growth of the market is the growing burden of cancer across the globe and the expanding biotech industry and research in cell biology. For instance, per an American Cancer Society 2022 update, 1,918,030 new cancer cases were estimated in the United States in 2022. Furthermore, cell analysis in cancer is widely used by researchers to identify various criteria. An article published in November 2022 in the Nature journal mentioned that researchers performed a pan-cancer analysis on 226 samples across 10 solid cancer types to profile the tumor microenvironment (TME) at single-cell resolution, illustrating the commonalities/plasticity of heterogenous CAFs (cancer-associated fibroblasts).
Furthermore, product launches, strategic collaborations, and acquisitions by key players are expected to drive market growth over the forecast period. For instance, in August 2022, DeNovix Inc, the manufacturer of the award-winning CellDrop Automated Cell Counter, developed two dedicated nuclei counting apps capable of differentiating isolated nuclei and intact cells from debris. The CellDrop Series is a line of image-based, automated cell counters. Systems include a high-definition 7-inch touchscreen for live preview and instant review of results.
While several developments predict growth, the high cost of cell analysis and complex regulatory scenarios are anticipated to restrain the market growth over the forecast period.
